TIL - Instil Bio to Present at Upcoming Investor Conferences in September

DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in September:

Morgan Stanley 19 ^th Annual Global Healthcare Conference
Fireside Chat: Thursday, September 9 at 2:00 p.m. ET

Baird’s 2021 Virtual Global Healthcare Conference
Company Presentation: Tuesday, September 14 at 5:30 p.m. ET

A live webcast, if recorded, of each presentation can be accessed under “News & Events” in the Investors section of the Company’s website at www.instilbio.com . The archived webcast will be available on the Company’s website shortly after the event.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.

Contacts:

Brendan Payne
Stern Investor Relations
1-212-362-1200
brendan.payne@sternir.com

Media Contact:
1-833-446-7845 Ext. 1009
mediarelations@instilbio.com